Anti-CD16 binding molecules

US9035026B2 · kind B2 · utility

Assignee

• AFFIMED GMBH · DE

Inventors

• Karin Hoffmann · Schwetzingen, DE
• Sergey Kipriyanov · Heidelberg, DE
• Stefan Knackmuss · Plankstadt, DE
• Fabrice Le Gall · Mainz, DE
• Melvyn Little · Büdelsdorf, DE
• Uwe Reusch · Maikammer, DE

Key dates

• Filing date: May 26, 2006
• Grant date: May 19, 2015
• Expiry date: Sep 2, 2029

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to binding molecules that specifically bind to the human Fc gamma receptor expressed on the surface of natural killer (NK) cells and macrophages (i.e. FcγRIIIA), and in particular binding molecules that specifically bind the A form FcγRIII but do not bind to the B form of FcγRIII, as well as to the use of such binding molecules in the diagnosis and treatment of disease. The invention further extends to polynucleotides encoding such binding molecules, host cells comprising such polynucleotides and methods of producing binding molecules of the invention using such host cells.